Vertex Pharmaceuticals ( VRTX 2.53%) has long been known as the company to turn to for life-saving cystic fibrosis (CF) drugs ...

Vertex Pharmaceuticals (NASDAQ ... offering patients a strong safety profile. The U.S. Food and Drug Administration (FDA) approved the drug for use in acute pain, but Vertex aims to eventually ...

Vertex Pharmaceuticals (NASDAQ:VRTX), a leading biotechnology company known for its cystic fibrosis (CF) treatments, is at a critical juncture as it seeks to diversify its portfolio and maintain its ...

Journave, the first non-addictive opioid-like pain medication, was developed based on Yale research from the ’90s.

Vertex Pharmaceuticals (NASDAQ ... which could limit the drug's accessibility. Moreover, if chronic pain indications are pursued in the future, significant price reductions may be necessary ...

Dean Maglaris, CEO of Cytogel Pharma Cytogel is inspired by broader progress & committed to innovating in the field of pain management, s ...

Europe to review safety data for Eisai-Biogen Alzheimer's drug Healthcare & Pharmaceuticalscategory· January 31, 2025 The U.S. Food and Drug Administration has approved Vertex Pharmaceuticals ...

Protest outside Meta’s London offices marks launch of Mad Youth Campaign, an effort by activists to challenge the ways in which corporate power negatively shapes the conditions young people live under ...

Lately, one of America's leading pharmaceutical companies can't catch a break from Wall Street. Shares of Vertex ...

In a report released yesterday, Jessica Fye from J.P. Morgan maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), with a ...